Allos Therapeutics to Announce 2006 Third Quarter Financial Results on Friday, November 3
02 11월 2006 - 6:00AM
PR Newswire (US)
WESTMINSTER, Colo., Nov. 1 /PRNewswire-FirstCall/ -- Allos
Therapeutics, Inc. (NASDAQ:ALTH), today announced that it will
report its 2006 third quarter financial results on Friday, November
3, 2006, before the open of the U.S. financial markets. Paul L.
Berns, President and Chief Executive Officer, and other members of
Allos' senior management will provide a company update and summary
of third quarter results via webcast and conference call on Friday,
November 3, 2006 at 11:00 AM ET. The dial in number for U.S.
residents to participate is 877-407-8031. International callers
should dial 201-689-8031. Participants should reference the Allos
Therapeutics conference call. An audio replay of the conference
call will be available from 5 PM ET on Friday, November 3, 2006,
until 11:59 PM ET on Friday, November 10, 2006. To access the
replay, please dial 877-660-6853 (domestic) or 201-612-7415
(international); Replay pass codes (both required for playback):
account # 286; conference ID # 218565. The webcast of this call
will be available from the homepage and the investors/media section
of the Company's web site, http://www.allos.com/ and will be
archived for 30 days. About Allos Therapeutics, Inc. Allos
Therapeutics, Inc. (ALTH) is a biopharmaceutical company focused on
the development and commercialization of small molecule
therapeutics for the treatment of cancer. The Company has two
product candidates in late-stage clinical development:
EFAPROXYN(TM) (efaproxiral), a radiation sensitizer currently under
evaluation in a pivotal Phase 3 trial in women with brain
metastases originating from breast cancer, and PDX (pralatrexate),
a novel, next generation antifolate currently under evaluation in a
pivotal Phase 2 trial in patients with relapsed or refractory
peripheral T-cell lymphoma. The Company is also evaluating RH1, a
targeted chemotherapeutic agent, in a Phase 1 trial in patients
with advanced solid tumors. For additional information, please
visit the Company's website at http://www.allos.com/. Safe Harbor
Statement The 2006 third quarter results press release and
conference call will contain forward-looking statements that
involve significant risks and uncertainties, including those that
can be found in the "Risk Factors" section of Allos' Form 10-K for
the year ended December 31, 2005 and in Allos' periodic reports on
Form 10-Q and Form 8-K. Allos is providing the information
contained in the press release and conference call as of the date
of the release and does not undertake any obligation to update any
forward- looking statements as a result of new information, future
events or otherwise. The Company cautions investors not to place
undue reliance on the forward- looking statements contained in the
press release or the conference call. No forward-looking statement
can be guaranteed and actual events and results may differ
materially from those projected. DATASOURCE: Allos Therapeutics,
Inc. CONTACT: Jennifer Neiman, Corporate Communications of Allos
Therapeutics, Inc., +1-720-540-5227, Web site:
http://www.allos.com/
Copyright
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024
Allos Therapeutics, Inc. (MM) (나스닥)의 실시간 뉴스: 최근 기사 0
More Allos Therapeutics (MM) News Articles